Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Related ARIA
Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals
Earnings Scheduled For November 5, 2014
Wayfair Rises, Westport Innovations Cuts Forecast (Fox Business)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Ariad Pharmaceuticals (NASDAQ: ARIA), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “With ponatinib approval for refractory/intolerant CML expected in U.S./EU in ~1Q13/3Q13, ARIA provided its commercial launch plan and a bit more details on ponatinib sales forecast, while refraining from providing profitability forecast (vs. our estimate of ~2016). Unlike ponatinib, AP26113 faces competition; we view its planned pivotal trial in ALK+ NSCLC in 2013 as important to maintain a competitive edge.”

Ariad Pharmaceuticals closed on Friday at $23.14.

Latest Ratings for ARIA

Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform
Jun 2014UBSMaintainsNeutral

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (ARIA)

Around the Web, We're Loving...

Get Benzinga's Newsletters